Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products

drug approval expired 70% Health

Alteogen Inc. has signed an option and license agreement with Novartis granting Novartis rights to develop and commercialize subcutaneous formulations using Alteogen’s Hybrozyme™ platform. This marks Alteogen’s fourth licensing agreement in 2026, emphasizing its platform expansion.

🇰🇷 Location: Daejeon — Sources: 1 — First seen: — Last seen:
Alteogen Novartis licensing agreement Hybrozyme biopharmaceutical

Contributing Articles